190 related articles for article (PubMed ID: 17885669)
1. Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans.
Lisovsky M; Hoang MP; Dresser KA; Kapur P; Bhawan J; Mahalingam M
Mod Pathol; 2008 Jan; 21(1):31-8. PubMed ID: 17885669
[TBL] [Abstract][Full Text] [Related]
2. D2-40, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans.
Bandarchi B; Ma L; Marginean C; Hafezi S; Zubovits J; Rasty G
Mod Pathol; 2010 Mar; 23(3):434-8. PubMed ID: 20062007
[TBL] [Abstract][Full Text] [Related]
3. High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors.
Hanly AJ; Jordà M; Elgart GW; Badiavas E; Nassiri M; Nadji M
Arch Pathol Lab Med; 2006 Jun; 130(6):831-4. PubMed ID: 16740036
[TBL] [Abstract][Full Text] [Related]
4. LN-2 (CD74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma.
Lazova R; Moynes R; May D; Scott G
Cancer; 1997 Jun; 79(11):2115-24. PubMed ID: 9179057
[TBL] [Abstract][Full Text] [Related]
5. Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberans.
West RB; Harvell J; Linn SC; Liu CL; Prapong W; Hernandez-Boussard T; Montgomery K; Nielsen TO; Rubin BP; Patel R; Goldblum JR; Brown PO; van de Rijn M
Am J Surg Pathol; 2004 Aug; 28(8):1063-9. PubMed ID: 15252314
[TBL] [Abstract][Full Text] [Related]
6. [Dermatofibrosarcoma Darier and Ferrand. Immunohistochemistry study of 38 cases. Research on a specific marker].
Declerck D; Claye C; Rotteleur G; Lecomte-Houcke M
Ann Pathol; 1997 Oct; 17(5):324-8. PubMed ID: 9471146
[TBL] [Abstract][Full Text] [Related]
7. Stromelysin 3 expression: a useful marker for the differential diagnosis dermatofibroma versus dermatofibrosarcoma protuberans.
Cribier B; Noacco G; Peltre B; Grosshans E
J Am Acad Dermatol; 2002 Mar; 46(3):408-13. PubMed ID: 11862177
[TBL] [Abstract][Full Text] [Related]
8. The Role of CD34 and D2-40 in the Differentiation of Dermatofibroma and Dermatofibrosarcoma Protuberans.
Sadullahoğlu C; Dere Y; Atasever TR; Öztop MT; Karaaslan Ö
Turk Patoloji Derg; 2017; 1(1):223-227. PubMed ID: 28832078
[TBL] [Abstract][Full Text] [Related]
9. Sclerosing Dermatofibrosarcoma Protuberans Shows Significant Overlap With Sclerotic Fibroma in Both Routine and Immunohistochemical Analysis: A Potential Diagnostic Pitfall.
Abdaljaleel MY; North JP
Am J Dermatopathol; 2017 Feb; 39(2):83-88. PubMed ID: 28134725
[TBL] [Abstract][Full Text] [Related]
10. From Morphea to Dermatofibrosarcoma Protuberans.
Crnarić I; Šitum M; Delaš Aždajić M; Vučić M; Buljan M
Acta Dermatovenerol Croat; 2022 Sep; 30(2):113-115. PubMed ID: 36254545
[TBL] [Abstract][Full Text] [Related]
11. Expression of CD163 in dermatofibroma, cellular fibrous histiocytoma, and dermatofibrosarcoma protuberans: comparison with CD68, CD34, and Factor XIIIa.
Sachdev R; Sundram U
J Cutan Pathol; 2006 May; 33(5):353-60. PubMed ID: 16640542
[TBL] [Abstract][Full Text] [Related]
12. Phosphohistone-H3 and Ki67: Useful Markers in Differentiating Dermatofibroma From Dermatofibrosarcoma Protuberans and Atypical Fibrohistiocytic Lesions.
Agarwal A; Gopinath A; Tetzlaff MT; Prieto VG
Am J Dermatopathol; 2017 Jul; 39(7):504-507. PubMed ID: 28609344
[TBL] [Abstract][Full Text] [Related]
13. Myxoid dermatofibroma on a great toe: a case report.
Moon A; Yoon N; Kim HS
Int J Clin Exp Pathol; 2015; 8(6):7605-9. PubMed ID: 26261677
[TBL] [Abstract][Full Text] [Related]
14. Expression of CD34 in sclerotic ("plywood") fibromas.
Hanft VN; Shea CR; McNutt NS; Pullitzer D; Horenstein MG; Prieto VG
Am J Dermatopathol; 2000 Feb; 22(1):17-21. PubMed ID: 10698210
[TBL] [Abstract][Full Text] [Related]
15. Tyrosinase expression in malignant melanoma, desmoplastic melanoma, and peripheral nerve tumors.
Boyle JL; Haupt HM; Stern JB; Multhaupt HA
Arch Pathol Lab Med; 2002 Jul; 126(7):816-22. PubMed ID: 12088451
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical markers in fibrohistiocytic lesions: factor XIIIa, CD34, S-100 and p75.
West KL; Cardona DM; Su Z; Puri PK
Am J Dermatopathol; 2014 May; 36(5):414-9. PubMed ID: 24162384
[TBL] [Abstract][Full Text] [Related]
17. [Giant cell fibroblastoma associated with Darier-Ferrand dermatofibrosarcoma in an adult].
Kourda M; Krichen H; Kennou H; Ben Yahia K; Ben Ayed M; Souissi R
Ann Dermatol Venereol; 1998 Apr; 125(4):255-6. PubMed ID: 9747262
[TBL] [Abstract][Full Text] [Related]
18. Microphthalmia-associated transcription factor (MiTF): Promiscuous staining patterns in fibrohistiocytic lesions is a potential pitfall.
Mohanty SK; Sharma S; Pradhan D; Kandukuri SR; Farahani N; Barry C; Wu JM; Frishberg D; Balzer B
Pathol Res Pract; 2018 Jun; 214(6):821-825. PubMed ID: 29773427
[TBL] [Abstract][Full Text] [Related]
19. Dermatofibrosarcoma protuberans is a unique fibrohistiocytic tumour expressing CD34.
Aiba S; Tabata N; Ishii H; Ootani H; Tagami H
Br J Dermatol; 1992 Aug; 127(2):79-84. PubMed ID: 1382538
[TBL] [Abstract][Full Text] [Related]
20. Myxoid dermatofibrosarcoma protuberans: clinicopathologic, immunohistochemical, and molecular analysis of eight cases.
Mentzel T; Schärer L; Kazakov DV; Michal M
Am J Dermatopathol; 2007 Oct; 29(5):443-8. PubMed ID: 17890911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
